There were plenty of reasons to be cheerful at Sanofi (Euronext: SAN) on Wednesday as the company presented its third-quarter 2018 results.
Shares in the French drugmaker were up nearly 5% in the early afternoon as markets digested results that showed a return to sales growth and prompted the company to improve its earnings-per-share estimate for the full year.
Using international financial reporting standards (IFRS), net sales for the quarter were 9.32 billion euros ($10.6 billion), an increase of 3.7%, on a reported basis, compared to the same period in 2017.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze